Abstract:HZ-H08905 is a first-class and potent CK1ε/PI3Kδ dual inhibitor with nano-molar inhibitory potency at the enzyme and cellular level. In vivo tumor growth inhibition is also observed in multiple B-cell lymphoma xenograft mouse model including OCI-LY10 and SU-DHL-6. HZ-H08905 has unique structure and activity profile distinct from other PI3Kδ inhibitors in development: 1) dual inhibition of CK1ε and PI3Kδ may exert synergistic effects through inhibiting both CK1ε/Wnt signaling and PI3K signaling in malignant lymphocytes, 2) dual inhibition of CK1ε and PI3Kδ also enhance anti-tumor immunity through regulation of tumor microenvironment; 3) preclinical studies also suggested an improved therapeutic window with a differentiated safety profile. HZ-H08905-101 is an ongoing Phase 1, first-in-human, open-label, multicenter, multiple-dose ascending and expansion study of oral HZ-H08905 monotherapy in patients with relapsed/ refractory advanced hematologic malignancies in China (CTR20213233). The aim of this study was to investigate the safety, tolerability, and pharmacokinetic properties of HZ-H08905, in order to determine the maximum tolerated dose (MTD) based on dose limiting toxicity (DLT) and assess preliminary anti-tumor activity in patients with non-Hodgkin lymphoma (NHL), including B-cell lymphoma and T-cell lymphoma. The phase Ia (dose escalation) part of the study was designed to determine MTD and recommended dose for expansion (RDE) of HZ-H08905. HZ-H08905 was administered orally once daily in 28-day cycles until disease progression or unacceptable toxicity. The dose escalation part was initiated with a dose titration in the initial cohort, followed by a 3 + 3 design. Efficacy evaluable patients included all dosed patients who underwent their first response evaluation or discontinued therapy. Response was assessed at the beginning of cycle 3 and then every 12 weeks from cycle 3 and every 24 weeks from cycle 18, and was measured according to IWWM-7 for WM, or IWCLL 2018 for CLL/SLL, or Lugano 2014 criteria for other NHL. Safety was assessed in all patients. The preliminary results showed that HZ-H08905 was well tolerated and showed clinical activity in patients with R/R NHL, especially R/R PTCL. The efficacy, safety, and tolerability of HZ-H08905 in R/R PTCL patients at recommended phase II dose (RP2D) established in the phase I dose escalation and expansion part will be investigated in phase 2.

Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors

Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors

Discovery of Potent and selective HPK1 Inhibitors Based on the 2,4-disubstituted Pyrimidine Scaffold with Immune Modulatory properties for Ameliorating T cell exhaustion

Discovery of 1(2H)-phthalazinone and 1(2H)-isoquinolinone derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors

Discovery of diaminotriazine carboxamides as potent inhibitors of hematopoetic progenitor kinase 1

Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody

Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1

Discovery of Novel PROTAC-Based HPK1 Degraders with High Potency and Selectivity for Cancer Immunotherapy

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor

Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress

Dual CK1/PI3K Inhibitor HZ-H08905, Exhibits As a Potential Therapeutic Strategy for Hematologic Malignancies

Opportunities and challenges for targeting HPK1 in cancer immunotherapy

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Design, synthesis and biological evaluation of methylenehydrazine-1-carboxamide derivatives with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold: Novel potential CDK9 inhibitors

Hybridization-based discovery of novel quinazoline-2-indolinone derivatives as potent and selective PI3Kα inhibitors

The Association Between Anti-Tumor Potency and Structure-Activity of Protein-Kinases Inhibitors Based on Quinazoline Molecular Skeleton

Abstract 3967: ISM9182A, a novel HPK1 inhibitor, exhibits immune modulatory activity and robust monotherapy anti-tumor effects in preclinical studies

Identification of Novel Piperazinylquinoxaline Derivatives As Potent Phosphoinositide 3-Kinase (PI3K) Inhibitors

Design, Synthesis, and Biological Evaluation of Pyrido[2,3- d ]pyrimidin-7(8 H )-one Derivatives As Potent USP1 Inhibitors

Design, Synthesis, and Structure-Activity Relationship of Novel Pyridazinone-Based PARP7/HDACs Dual Inhibitors for Elucidating the Relationship between Antitumor Immunity and HDACs Inhibition